Chinese pharmaceutical BD achieves another milestone! Abogen Biosciences and Novartis reach a $7.8 billion mRNA licensing agreement.

Chinese mRNA biotechnology company Abogen Biosciences has entered into a licensing agreement with Swiss pharmaceutical giant Novartis worth up to $7.8 billion , making it one of the largest deals in the world. This has become another significant case of multinational pharmaceutical companies betting on China's innovative drug pipeline recently.

Under the agreement, Novartis will pay an upfront $575 million for exclusive rights to Abogen Biosciences' investigational drug ABO2203, and will have options for other potential projects on Abogen Biosciences' RNA technology platform. If subsequent development progresses smoothly and regulatory approvals are obtained, Abogen Biosciences could receive up to an additional $7.2 billion in milestone payments, and is also expected to receive royalties from future product sales.

ABO2203 is an mRNA-encoded T-cell engager that aims to fundamentally reset the immune system by enabling patients to produce therapeutic molecules that target and eliminate B cells that drive autoimmune diseases. Potential indications for this drug include a variety of autoimmune diseases such as lupus and rheumatoid arthritis .

This transaction further demonstrates the continued high level of attention multinational pharmaceutical companies pay to China's innovative drug pipeline, and also signifies that the commercial value of China's mRNA technology platform has been officially recognized by top international pharmaceutical companies.

Transaction structure: $575 million upfront payment, milestone total of $7.8 billion.

This collaboration adopts a typical "down payment + milestone payment + royalty" structure.

Novartis will pay an upfront payment of $575 million in exchange for exclusive development and commercialization rights to ABO2203, along with an option to license other potential projects on Abogen Biosciences' RNA platform.

If ABO2203 successfully completes all phases of clinical development and obtains regulatory approval, Abogen Biosciences could receive up to $7.2 billion in milestone payments. Furthermore, Abogen Biosciences is expected to collect royalties from future product sales, further expanding its potential revenue streams.

Core asset: mRNA-encoded T-cell connectives targeting autoimmune diseases.

ABO2203 represents a cutting-edge exploration of mRNA technology in the field of autoimmune diseases.

According to Bloomberg, the drug is an mRNA-encoded T-cell connector that works by guiding the patient's own immune system to produce therapeutic molecules that target and eliminate B cells—white blood cells that are a core driver of autoimmune diseases such as lupus and rheumatoid arthritis. By depleting pathogenic B cells, ABO2203 aims to fundamentally reset the immune system, rather than merely suppressing symptoms.

Novartis has previously explored various immune reset pathways in the field of autoimmune diseases, including cell therapy. However, according to Bloomberg, the company recently suspended its clinical trials of related cell therapies due to the deaths of three patients . This shift to mRNA technology may reflect a strategic adjustment in Novartis's autoimmune pipeline.

Multinational pharmaceutical companies continue to bet on China's innovative drug pipeline

The deal between Abogen Biosciences and Novartis is a microcosm of the recent flurry of multinational pharmaceutical companies' moves to invest in innovative drugs in China.

According to Bloomberg, just this week, Novo Nordisk acquired the rights to an early-stage obesity oral drug from Jiangsu Hengrui Medicine for $2.6 billion ; AstraZeneca invested $2 billion in Summit Therapeutics to jointly develop a cancer drug derived from Akeso ; and previously, GlaxoSmithKline (GSK) also reached a licensing agreement with Chimagen Biosciences for up to $750 million for a blood cancer drug.

The rapid completion of these transactions reflects the structural demand of major global pharmaceutical companies for innovative Chinese drug pipelines. Against the backdrop of pressure on their own R&D pipelines, Chinese biotechnology companies, with their differentiated technology platforms and relatively competitive licensing terms, are becoming an important source for multinational pharmaceutical companies to supplement their pipelines.

Risk Warning and DisclaimerInvesting involves risk; please exercise caution. This article does not constitute personal investment advice and does not take into account the specific investment objectives, financial situation, or needs of individual users. Users should consider whether any opinions, views, or conclusions in this article are suitable for their specific circumstances. Any investment decisions made based on this information are at your own risk.